Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pathway to Cures (P2C) serves as the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF), established to expedite the development of cures and therapies for inheritable blood and bleeding disorders. Founded to address the critical funding gap in early-stage therapy development, P2C operates independently while utilizing the resources and expertise of NBDF. The organization is headquartered at 1230 Avenue of the Americas, 16th Floor, New York, NY 10020.
Currently, P2C focuses on early-stage funding opportunities, specifically in the pre-seed, seed, and seed-plus stages. Although specific metrics such as fund size or portfolio count are not disclosed, P2C's strategic investments cover a range of innovative therapies targeting various inheritable blood disorders. The organization has made significant strides in the biotech and healthcare sectors, aiming to attract additional capital from traditional venture capital, biotech, and pharmaceutical entities.
P2C invests in companies that demonstrate the potential to develop innovative therapies and technologies specifically for inheritable blood and bleeding disorders. Their investment strategy emphasizes early-stage funding opportunities, targeting sectors such as biotech and healthcare. The organization is particularly interested in therapeutic approaches that include RNA technology, engineered B-cells, and non-invasive medical devices.
In addition to these therapeutic focuses, P2C seeks to attract further investment from traditional venture capital and pharmaceutical entities, enhancing the development of groundbreaking therapies. Their commitment to addressing the funding gap in early-stage therapy development positions them as a key player in the biotech landscape, particularly for startups innovating in the treatment of blood disorders.
P2C's portfolio includes investments in several strategic areas aimed at addressing inheritable blood disorders:
Teri Willey: Managing Director & Officer at Pathway to Cures, brings extensive experience in venture philanthropy and healthcare investments.
Michael Recht, MD, PhD, MBA: Chair of the Scientific Advisory Group and Chief Medical and Scientific Advisor, he has a strong background in medical research and clinical practice.
Tim Brent, MBA: Venture Principal, Tim has a track record in early-stage investments and strategic partnerships in the biotech sector.
Leonard Valentino, MD: Entrepreneur in Residence, Leonard has significant expertise in clinical development and commercialization of therapies.
Peter Harvey, MBA: Chief Financial Officer and Chief Business Officer of NBDF, Peter oversees financial operations and strategic initiatives.
Beth Whitehouse: Senior Vice President for Advancement at NBDF, Beth focuses on fundraising and community engagement efforts.
To pitch Pathway to Cures, founders should send an email to info@pathwaytocures.org. A well-structured pitch deck is essential, including details about the technology, market opportunity, and team qualifications. While specific response times are not guaranteed, prompt communication is encouraged.
Warm introductions are beneficial but not mandatory. Founders should ensure that their pitch clearly articulates the innovative aspects of their therapy and its relevance to inheritable blood disorders.
Recently, Pathway to Cures announced a partnership with Spark Biomedical to launch the LUNA Trial, which aims to explore non-pharmaceutical options for heavy menstrual bleeding. This initiative reflects P2C's commitment to advancing research and developing innovative therapies.
Additionally, P2C has published insights on building better therapies through patient panels, demonstrating their engagement with the community and dedication to improving treatment outcomes for blood disorders. Updates on their annual fund have also been shared, highlighting their ongoing efforts to support research and development in this critical area.
What are Pathway to Cures' investment criteria?
P2C focuses on early-stage companies developing innovative therapies for inheritable blood and bleeding disorders. They seek to invest in technologies that address significant medical needs in these areas.
How can I apply or pitch to Pathway to Cures?
Founders can reach out via email at info@pathwaytocures.org to discuss potential investment opportunities. A detailed pitch deck outlining the technology, market potential, and team is recommended.
What makes Pathway to Cures different from other investors?
P2C operates as a venture philanthropy fund, leveraging the resources of the National Bleeding Disorders Foundation to fill the funding gap in early-stage therapy development. Their focus on inheritable blood disorders sets them apart in the biotech investment landscape.
What is the geographic scope of Pathway to Cures' investments?
P2C primarily invests in North America, targeting companies that are innovating in the biotech and healthcare sectors.
What is the typical check size for investments?
While specific check sizes are not disclosed, P2C targets early-stage funding opportunities, which typically range from pre-seed to seed-plus stages.
What kind of post-investment involvement can founders expect?
P2C engages with portfolio companies to provide support and resources, leveraging the expertise of the National Bleeding Disorders Foundation to assist in the development of therapies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.